You are here

P&T December 2015

Features

The Impact on Providers and Patients Is Either Mixed or Unclear

Anthem and Cigna, Aetna and Humana, Walgreens and Rite Aid, Valeant and Salix—the pace of health care mergers is dizzying. Aspects of health care reform that encourage “integrated care” explain some of the frenzy, but by no means all of it.

About one in four U.S. adults has elevated triglyceride (TG) levels. Approved prescription omega-3 fatty acid products are an effective option for treating high TG levels; this commentary summarizes their pharmacology, efficacy, and safety.

Part 5: Treatment of Nonmotor Complications

Most patients with Parkinson’s disease experience nonmotor complications, broadly classified as either neuropsychiatric presentations or autonomic disorders. Despite the prevalence of these nonmotor features, treatment options for them are limited.

Opioids are often used to relieve pain after surgery, but they are associated with serious adverse effects. In this retrospective chart-review analysis, the use of intravenous acetaminophen did not reduce opioid use following bariatric surgery.

To make educated recommendations based on published clinical practice guidelines (CPGs), clinicians must understand the guideline development process. This article seeks to help clinicians interpret CPGs using the available evaluation methods.

Departments

Medication Errors

A clinical reminder about the safe use of insulin vials

Prescription: Washington

Pharmacists are the focus of drug adherence pilot program.

FDA approvals, drug indications, and updates

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for diabetes

Drug Forecast

Ivabradine (Corlanor) for heart failure: the first selective and specific If inhibitor